

PRESS RELEASE

13 March 2025

EQT completes sale of shares in Galderma Group AG

- The sale resulted in aggregate gross proceeds of c. CHF 1.3 billion, of which EQT received c. CHF 354 million

Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce the completion of the placement of 15,000,000 shares in Galderma Group AG (SIX: GALD) (the "Company") (the "Shares") for aggregate gross proceeds of c. CHF 1.3 billion via an accelerated bookbuilding process (the "Placement").

As part of the Placement, EQT received gross proceeds of c. CHF 354 million. The Placement was completed on 13 March 2025. BNP Paribas, BofA Securities, Goldman Sachs, Morgan Stanley and UBS acted as joint global coordinators and joint bookrunners for the Placement.

Contact

EQT Press Office, press@eqtpartners.com

Important notice

This press release does not constitute (i) an offer to sell or a solicitation of an offer to buy any securities of Galderma Group AG or any of its affiliates and it does not constitute a prospectus within the meaning of the Swiss Financial Services Act or (ii) an offer of securities for sale in the United States or elsewhere. Securities may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration. There will be no public offering of any of the securities mentioned in this press release in the United States.

About EQT

EQT is a purpose-driven global investment organization with EUR 269 billion in total assets under management (EUR 136 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com

Follow EQT on [LinkedIn](#), [X](#), [YouTube](#) and [Instagram](#)

About Galderma Group AG

Galderma Group AG is a pure-play leader in the dermatology category, with a presence in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that cover the full spectrum of the rapidly growing dermatology market. This includes Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body's largest organ – the skin – addressing individual consumer and patient needs with superior outcomes in collaboration with healthcare professionals.